Vitamin D pediatric oncology study opens recruiting on gut microbiome and metabolome
A recruiting pediatric oncology study will examine whether Vitamin D is linked to gut microbiome diversity and metabolome changes, with results not yet posted.
A pediatric oncology study looking at Vitamin D and the gut microbiome is now listed as RECRUITING, and that matters because it points to another active effort to understand how treatment may interact with the body’s bacteria and related chemistry. The latest registry observation was published 2026-11-16T00:00:00+00:00, and it notes that results have not been posted yet.
The study is titled Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology Patients and is sponsored by Children's Hospital of Orange County. Its primary outcome is Gut microbiome diversity, measured through study completion, up to 97 days.
"This record describes a study and its registry status; study outcomes require posted results."
What the study is set to measure
The registry entry says bacterial 16S ribosomal RNA gene targeted sequencing will be used with the Quick-16S™ NGS Library Prep Kit (Zymo Research, Irvine, CA). In plain terms, that means the study is using a lab method that reads part of bacterial DNA so researchers can compare which microbes are present.
The description also says the bioinformatic analysis includes Absolute Abundance, Composition barplots, Taxonomy Heatmaps, Alpha and Beta Diversity, and LEfSe Analysis. Those are data-analysis steps for looking at how many microbes there are, how they are grouped, and how similar or different the samples appear.
"Bioinformatic analysis includes Absolute Abundance, Composition barplots, Taxonomy Heatmaps, Alpha and Beta Diversity, and LEfSe Analysis."
How this fits into Cancer Breakthroughs
The study appears in the active special event Cancer Breakthroughs, alongside other cancer-related registry observations. That broader context does not change the study’s meaning, but it shows that pediatric oncology research is being tracked together with other live cancer studies.
For readers, the practical takeaway is simple: this is an early-stage registry listing, not a finished result. The study has a primary completion date of 2027-08-31, marked ESTIMATED, so the clearest near-term signal is that recruitment is open and the outcomes are still ahead.
"Study outcomes require posted results."
Why it is worth watching
Vitamin D is the headline ingredient here, but the registry entry is really about whether researchers can connect it with changes in gut microbiome diversity and metabolome measures. The metabolome is the collection of small molecules in the body, so this kind of study tries to map both microbes and chemical byproducts at the same time.
Because there are no posted results yet, the study should be read as a live research effort rather than evidence for a benefit. Still, the combination of recruiting status, a defined microbiome endpoint, and a measured timeline gives families and followers of pediatric cancer research a concrete reason to keep an eye on the listing.
"This record describes a study and its registry status; study outcomes require posted results."